학술논문
The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers
Document Type
Article
Author
Source
In: Molecular Cancer Therapeutics . (Molecular Cancer Therapeutics, 1 March 2015, 14(3):692-703)
Subject
Language
English
ISSN
15388514
15357163
15357163